These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 21419202)

  • 1. Physical state and dissolution of ibuprofen formulated by co-spray drying with mesoporous silica: effect of pore and particle size.
    Shen SC; Ng WK; Chia L; Hu J; Tan RB
    Int J Pharm; 2011 May; 410(1-2):188-95. PubMed ID: 21419202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stabilized amorphous state of ibuprofen by co-spray drying with mesoporous SBA-15 to enhance dissolution properties.
    Shen SC; Ng WK; Chia L; Dong YC; Tan RB
    J Pharm Sci; 2010 Apr; 99(4):1997-2007. PubMed ID: 19816955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of particle morphology, pore size and surface coating of mesoporous silica on Naproxen dissolution rate enhancement.
    Guo Z; Liu XM; Ma L; Li J; Zhang H; Gao YP; Yuan Y
    Colloids Surf B Biointerfaces; 2013 Jan; 101():228-35. PubMed ID: 23010024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel strategy to design sustained-release poorly water-soluble drug mesoporous silica microparticles based on supercritical fluid technique.
    Li-Hong W; Xin C; Hui X; Li-Li Z; Jing H; Mei-Juan Z; Jie L; Yi L; Jin-Wen L; Wei Z; Gang C
    Int J Pharm; 2013 Sep; 454(1):135-42. PubMed ID: 23871738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physical state of poorly water soluble therapeutic molecules loaded into SBA-15 ordered mesoporous silica carriers: a case study with itraconazole and ibuprofen.
    Mellaerts R; Jammaer JA; Van Speybroeck M; Chen H; Van Humbeeck J; Augustijns P; Van den Mooter G; Martens JA
    Langmuir; 2008 Aug; 24(16):8651-9. PubMed ID: 18630936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solid State NMR Characterization of Ibuprofen:Nicotinamide Cocrystals and New Idea for Controlling Release of Drugs Embedded into Mesoporous Silica Particles.
    Skorupska E; Kaźmierski S; Potrzebowski MJ
    Mol Pharm; 2017 May; 14(5):1800-1810. PubMed ID: 28403609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High drug load, stable, manufacturable and bioavailable fenofibrate formulations in mesoporous silica: a comparison of spray drying versus solvent impregnation methods.
    Hong S; Shen S; Tan DC; Ng WK; Liu X; Chia LS; Irwan AW; Tan R; Nowak SA; Marsh K; Gokhale R
    Drug Deliv; 2016; 23(1):316-27. PubMed ID: 24853963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comminution of ibuprofen to produce nano-particles for rapid dissolution.
    Plakkot S; de Matas M; York P; Saunders M; Sulaiman B
    Int J Pharm; 2011 Aug; 415(1-2):307-14. PubMed ID: 21683776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesoporous silica material TUD-1 as a drug delivery system.
    Heikkilä T; Salonen J; Tuura J; Hamdy MS; Mul G; Kumar N; Salmi T; Murzin DY; Laitinen L; Kaukonen AM; Hirvonen J; Lehto VP
    Int J Pharm; 2007 Feb; 331(1):133-8. PubMed ID: 17046183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of mesoporous silicon and non-ordered mesoporous silica materials as drug carriers for itraconazole.
    Kinnari P; Mäkilä E; Heikkilä T; Salonen J; Hirvonen J; Santos HA
    Int J Pharm; 2011 Jul; 414(1-2):148-56. PubMed ID: 21601623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and characterization of ibuprofen solid lipid nanoparticles with enhanced solubility.
    Potta SG; Minemi S; Nukala RK; Peinado C; Lamprou DA; Urquhart A; Douroumis D
    J Microencapsul; 2011; 28(1):74-81. PubMed ID: 21171818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of amorphous microporous silica for ibuprofen controlled release.
    Aerts CA; Verraedt E; Depla A; Follens L; Froyen L; Van Humbeeck J; Augustijns P; Van den Mooter G; Mellaerts R; Martens JA
    Int J Pharm; 2010 Sep; 397(1-2):84-91. PubMed ID: 20619331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploitation of 3D face-centered cubic mesoporous silica as a carrier for a poorly water soluble drug: influence of pore size on release rate.
    Zhu W; Wan L; Zhang C; Gao Y; Zheng X; Jiang T; Wang S
    Mater Sci Eng C Mater Biol Appl; 2014 Jan; 34():78-85. PubMed ID: 24268236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-Field NMR to Characterize the Crystalline State of Ibuprofen Confined in Ordered or Nonordered Mesoporous Silica.
    Okada K; Hayashi Y; Tsuji T; Onuki Y
    Chem Pharm Bull (Tokyo); 2022; 70(8):550-557. PubMed ID: 35908921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesoporous silica nanoparticles with manipulated microstructures for drug delivery.
    Chen Z; Li X; He H; Ren Z; Liu Y; Wang J; Li Z; Shen G; Han G
    Colloids Surf B Biointerfaces; 2012 Jun; 95():274-8. PubMed ID: 22494670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of the physical state of drug molecules in mesoporous silicon with different surface chemistries.
    Riikonen J; Mäkilä E; Salonen J; Lehto VP
    Langmuir; 2009 Jun; 25(11):6137-42. PubMed ID: 19466777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facile synthesis of 3D cubic mesoporous silica microspheres with a controllable pore size and their application for improved delivery of a water-insoluble drug.
    Hu Y; Wang J; Zhi Z; Jiang T; Wang S
    J Colloid Interface Sci; 2011 Nov; 363(1):410-7. PubMed ID: 21820127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles.
    Limnell T; Riikonen J; Salonen J; Kaukonen AM; Laitinen L; Hirvonen J; Lehto VP
    Int J Pharm; 2007 Oct; 343(1-2):141-7. PubMed ID: 17600644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical approach to prepare solid dispersion drug product using spherical silicate.
    Nagane K; Kimura S; Ukai K; Ogawa N; Yamamoto H
    Int J Pharm; 2014 Nov; 475(1-2):364-71. PubMed ID: 25131150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luminescence functionalization of SBA-15 by YVO4:Eu3+ as a novel drug delivery system.
    Yang P; Huang S; Kong D; Lin J; Fu H
    Inorg Chem; 2007 Apr; 46(8):3203-11. PubMed ID: 17371013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.